(Q38412535)

English

Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression

scientific article published on 09 September 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

2 September 2017

Synthetic TRP2 long-peptide and α-galactosylceramide formulated into cationic liposomes elicit CD8+ T-cell responses and prevent tumour progression (English)

1 reference

Europe PubMed Central

2 September 2017

tumor progression

1 reference

based on heuristic

inferred from title

Regan J. Anderson

object named as

Regan Anderson

4

0 references

author name string

Silke Neumann

1

1 reference

Europe PubMed Central

2 September 2017

Katie Young

2

1 reference

Europe PubMed Central

2 September 2017

Benji Compton

3

1 reference

Europe PubMed Central

2 September 2017

Gavin Painter

5

1 reference

Europe PubMed Central

2 September 2017

Sarah Hook

6

1 reference

Europe PubMed Central

2 September 2017

language of work or name

0 references

publication date

9 September 2015

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

33

1 reference

Europe PubMed Central

2 September 2017

43

1 reference

Europe PubMed Central

2 September 2017

5838-5844

1 reference

Europe PubMed Central

2 September 2017

Recent developments in cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Therapeutic cancer vaccines: are we there yet?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Vaccines against advanced melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Immunological mechanisms of vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Peptide vaccination can lead to enhanced tumor growth through specific T-cell tolerance induction.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

The contrasting roles of NKT cells in tumor immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

CD1: antigen presentation and T cell function

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Invariant NKT cells amplify the innate immune response to lipopolysaccharide.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Sequential production of interferon-gamma by NK1.1+ T cells and natural killer cells is essential for the antimetastatic effect of alpha -galactosylceramide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Clinical experience with α-galactosylceramide (KRN7000) in patients with advanced cancer and chronic hepatitis B/C infection.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Potent anti-tumor responses to immunization with dendritic cells loaded with tumor tissue and an NKT cell ligand.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

The regulation of human MMP-13 by licofelone, an inhibitor of cyclo-oxygenases and 5-lipoxygenase, in human osteoarthritic chondrocytes is mediated by the inhibition of the p38 MAP kinase signalling pathway

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Glycolipid alpha-C-galactosylceramide is a distinct inducer of dendritic cell function during innate and adaptive immune responses of mice

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Activation of natural killer T cells by alpha-galactosylceramide rapidly induces the full maturation of dendritic cells in vivo and thereby acts as an adjuvant for combined CD4 and CD8 T cell immunity to a coadministered protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

The nanoparticulation by octaarginine-modified liposome improves α-galactosylceramide-mediated antitumor therapy via systemic administration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Harnessing invariant NKT cells in vaccination strategies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Nanoparticle formulated alpha-galactosylceramide activates NKT cells without inducing anergy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Particulate delivery systems for vaccines: what can we expect?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Immunostimulation of dendritic cells by cationic liposomes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Influence of liposomal size, lipid compostion and lipid dose

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Pegylation of DDA:TDB liposomal adjuvants reduces the vaccine depot effect and alters the Th1/Th2 immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Diffusion of univalent ions across the lamellae of swollen phospholipids

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Efficient synthesis of alpha-galactosyl ceramide analogues using glycosyl iodide donors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

A method for the incorporation of ovalbumin into immune stimulating complexes prepared by the hydration method

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Physical Characterization of Synthetic Phosphatidylinositol Dimannosides and Analogues in Binary Systems with Phosphatidylcholine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Novel murine dendritic cell lines: a powerful auxiliary tool for dendritic cell research.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

An invariant T cell receptor alpha chain is used by a unique subset of major histocompatibility complex class I-specific CD4+ and CD4-8- T cells in mice and humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Modified thermoresponsive Poloxamer 407 and chitosan sol–gels as potential sustained-release vaccine delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Cationic liposomes loaded with proapoptotic peptide D-(KLAKLAK)(2) and Bcl-2 antisense oligodeoxynucleotide G3139 for enhanced anticancer therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Adjuvant effect of cationic liposomes for subunit influenza vaccine: influence of antigen loading method, cholesterol and immune modulators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Comparison of the Depot Effect and Immunogenicity of Liposomes Based on Dimethyldioctadecylammonium (DDA), 3β-[N-(N′,N′-Dimethylaminoethane)carbomyl] Cholesterol (DC-Chol), and 1,2-Dioleoyl-3-trimethylammonium Propane (DOTAP): Prolonged Liposome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

CD1 recognition by mouse NK1+ T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Alpha-galactosylceramide is an effective mucosal adjuvant for repeated intranasal or oral delivery of HIV peptide antigens.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Natural killer T cell ligand alpha-galactosylceramide enhances protective immunity induced by malaria vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Virus-like particles and α-galactosylceramide form a self-adjuvanting composite particle that elicits anti-tumor responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2015.08.083

7 January 2021

Identifiers

10.1016/J.VACCINE.2015.08.083

1 reference

Europe PubMed Central

2 September 2017

1 reference

Europe PubMed Central

2 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38412535&oldid=2070853422"